🇺🇸 Gabapentin enacarbil extended release in United States

10 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Blood Pressure Fluctuation — 1 report (10%)
  2. Blood Pressure Increased — 1 report (10%)
  3. Chest Discomfort — 1 report (10%)
  4. Condition Aggravated — 1 report (10%)
  5. Feeling Abnormal — 1 report (10%)
  6. Headache — 1 report (10%)
  7. Hypertension — 1 report (10%)
  8. Migraine — 1 report (10%)
  9. Tremor — 1 report (10%)
  10. Ulcer — 1 report (10%)

Source database →

Gabapentin enacarbil extended release in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Gabapentin enacarbil extended release approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Gabapentin enacarbil extended release in United States?

Theresa Zesiewicz, MD is the originator. The local marketing authorisation holder may differ — check the official source linked above.